title: Comment on "No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance" by Ubaldo Visco-Comandini et al. [Dig. Liver Dis. 2014;46:348-52].
authors.affiliation: Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Islamic Republic of Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Keshvari
authors.affiliation: Middle East Liver Disease (MELD) Center, Tehran, Islamic Republic of Iran.
authors.forename: Heidar
authors.initials: H
authors.lastname: Sharafi
authors.affiliation: Middle East Liver Disease (MELD) Center, Tehran, Islamic Republic of Iran. Electronic address: alavian@thc.ir.
authors.forename: Seyed Moayed
authors.initials: SM
authors.lastname: Alavian
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006508:Hepatitis Antibodies / Q000276:immunology*; D019701:Hepatitis D, Chronic / Q000188:drug therapy*; D003698:Hepatitis Delta Virus / Q000276:immunology*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007378:Interleukins / Q000235:genetics*; D008297:Male; D012367:RNA, Viral / Q000097:blood*
chemical_list: D000998:Antiviral Agents; D006508:Hepatitis Antibodies; D016898:Interferon-alpha; D007378:Interleukins; D012367:RNA, Viral